Kairos Pharma, LTD.’s Lock-Up Period Set To End Tomorrow (NYSEAMERICAN:KAPA)

Kairos Pharma’s (NYSEAMERICAN:KAPAGet Free Report) lock-up period is set to expire on Monday, March 17th. Kairos Pharma had issued 1,550,000 shares in its initial public offering on September 16th. The total size of the offering was $6,200,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Analysts Set New Price Targets

Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, February 26th.

Read Our Latest Report on KAPA

Kairos Pharma Price Performance

Shares of KAPA opened at $0.99 on Friday. The firm’s 50 day simple moving average is $1.40. Kairos Pharma has a 12 month low of $0.85 and a 12 month high of $4.00.

About Kairos Pharma

(Get Free Report)

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.

Read More

Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.